The mode of action for the current seasonal influenza vaccines is the generation of neutralizing antibodies against the major surface glycoprotein hemagglutinin (HA), commonly quantified by the hemagglutinin inhibition (HI) assay and used as the traditional correlate of protection [3,26]. This evidence concerns the gene ART4 and influenza.